FDA Gives Innovation, Harmonization Added Attention In Final Priorities Report
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry comments lead to subtle but notable changes; agency also makes a few deletions, additions of its own including deemphasizing cost-control projects, highlighting antibiotic development and changing the status of its facility improvements.